Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Shocks Expected In EU Quality Guidance For Drug-Device Combinations

Executive Summary

Long-awaited draft EU guidance on the quality requirements for integral and non-integral drug-device combination products will be published very soon.

You may also be interested in...



Advice At Last For Drug Makers Worried About New Medical Device Rules

An upcoming requirement that Europe’s new medical device regulation has introduced for companies making drugs with integral medical devices will not be applied retrospectively, according to the European Medicines Agency.

Find Your EU Notified Body Now Or Risk A ‘Nasty Surprise’

Companies developing drugs with integral medical devices such as pre-filled syringes in the EU are desperate for guidance on how to comply with a provision that Europe’s new Medical Device Regulation will introduce for them. Speakers at a regulatory conference in Sweden had some important advice for them.

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Topics

UsernamePublicRestriction

Register

PS125328

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel